Phoqus today announces its preliminary results for the year ended 31 December 2007.

Phoqus Pharmaceuticals Announces Positive Results from a Phase II study of its Novel Cortisol Replacement Therapy, Chronocort® in Congenital Adrenal Hyperplasia

Phoqus Pharmaceuticals announces it has appointed Michel Grandjean to the position of Chief Operating Officer

Phoqus Pharmaceuticals announces it has appointed Dr Patrick Round to the position of Chief Medical Officer

Phoqus Pharmaceuticals today announces an update on the progress and design of the clinical trial programme for Chronocort™

Phoqus Pharmaceuticals today announces its interim results for the six months ended 30 June 2007.

Phoqus Pharmaceuticals announces that the Company's name was changed from Phoqus Group plc to Phoqus Pharmaceuticals plc.

Phoqus announces the results of the Extraordinary General Meeting.

Phoqus receives IND from FDA and initiates Phase II clinical trial of Chronocort™ in patients with Congenital Adrenal Hyperplasia at the US National Institutes of Health.

Phoqus announces the Board’s proposal to change the Company’s name to Phoqus Pharmaceuticals plc.